{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T22:49:37Z","timestamp":1791326977048,"version":"4.3.1"},"reference-count":54,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:00:00Z","timestamp":1639094400000},"content-version":"vor","delay-in-days":9,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81871894"],"award-info":[{"award-number":["81871894"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["91942314"],"award-info":[{"award-number":["91942314"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cancer"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cis-diamminedichloro-platinum (CDDP)-based chemotherapy regimens are the most predominant treatment strategies for patients with esophageal squamous cell carcinoma (ESCC). Dysregulated long non-coding RNAs (lncRNAs) contribute to CDDP resistance, which results in treatment failure in ESCC patients. However, the majority of lncRNAs involved in CDDP resistance in ESCC remain to be elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>The public Gene Expression Omnibus (GEO) dataset GSE45670 was analysed to reveal potential lncRNAs involved in CDDP resistance of ESCC. Candidate upregulated lncRNAs were detected in ESCC specimens by qRT-PCR to identify crucial lncRNAs. Non-coding RNA activated by DNA damage (NORAD) was selected for further study. Kaplan-Meier analysis and a COX proportional regression model were performed to analyse the potential of NORAD for predicting prognosis of ESCC patients. The role of NORAD in CDDP resistance were determined by conducting gain and loss-of-function experiments in vitro. Fluorescence in situ hybridization (FISH) was performed to determine the subcellular location of NORAD in ESCC cells. A public GEO dataset and bioinformatic algorithms were used to predict the microRNAs (miRNAs) that might be latently sponged by NORAD. qRT-PCR was conducted to verify the expression of candidate miRNAs. Luciferase reporter and Argonaute-2 (Ago2)-RNA immunoprecipitation (RIP) assays were conducted to evaluate the interaction between NORAD and candidate miRNAs. A miRNA rescue experiment was performed to authenticate the NORAD regulatory axis and its effects on CDDP resistance in ESCC cells. Western blotting was conducted to confirm the precise downstream signalling pathway of NORAD. A xenograft mouse model was established to reveal the effect of NORAD on CDDP resistance in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The expression of NORAD was higher in CDDP-resistant ESCC tissues and cells than in CDDP-sensitive tissues and cells. NORAD expression was negatively correlated with the postoperative prognosis of ESCC patients who underwent CDDP-based chemotherapy. NORAD knockdown partially arrested CDDP resistance of ESCC cells. FISH showed that NORAD was located in the cytoplasm in ESCC cells. Furthermore, overlapping results from bioinformatic algorithms analyses and qRT-PCR showed that NORAD could sponge miR-224-3p in ESCC cells. Ago2-RIP demonstrated that NORAD and miR-224-3p occupied the same Ago2 to form an RNA-induced silencing complex (RISC) and subsequently regulated the expression of metadherin (MTDH) in ESCC cells. The NORAD\/miR-224-3p\/MTDH axis promoted CDDP resistance and progression in ESCC cells by promoting nuclear accumulation of \u03b2-catenin in vitro and in vivo.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>NORAD upregulates MTDH to promote CDDP resistance and progression in ESCC by sponging miR-224-3p. Our results highlight the potential of NORAD as a therapeutic target in ESCC patients receiving CDDP-based chemotherapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12943-021-01455-y","type":"journal-article","created":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:03:12Z","timestamp":1639094592000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":72,"title":["Long non-coding RNA NORAD\/miR-224-3p\/MTDH axis contributes to CDDP resistance of esophageal squamous cell carcinoma by promoting nuclear accumulation of \u03b2-catenin"],"prefix":"10.1186","volume":"20","author":[{"given":"Yunlong","family":"Jia","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongyan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Lv","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuqing","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zishuo","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuexiao","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tianxu","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiali","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1201-4624","authenticated-orcid":false,"given":"Lihua","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,10]]},"reference":[{"key":"1455_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21590","volume":"70","author":"RL Siegel","year":"2020","unstructured":"Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70:7\u201330.","journal-title":"CA Cancer J Clin"},{"key":"1455_CR2","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","volume":"391","author":"C Allemani","year":"2018","unstructured":"Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Niksic M, et al. Global surveillance of trends in cancer survival 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018;391:1023\u201375.","journal-title":"Lancet"},{"key":"1455_CR3","doi-asserted-by":"crossref","first-page":"1727","DOI":"10.3389\/fonc.2020.01727","volume":"10","author":"J Yang","year":"2020","unstructured":"Yang J, Liu X, Cao S, Dong X, Rao S, Cai K. Understanding esophageal Cancer: the challenges and opportunities for the next decade. Front Oncol. 2020;10:1727.","journal-title":"Front Oncol"},{"key":"1455_CR4","doi-asserted-by":"crossref","first-page":"2010","DOI":"10.1002\/1878-0261.12548","volume":"13","author":"RJ Zeng","year":"2019","unstructured":"Zeng RJ, Zheng CW, Gu JE, Zhang HX, Xie L, Xu LY, et al. RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes. Mol Oncol. 2019;13:2010\u201330.","journal-title":"Mol Oncol"},{"key":"1455_CR5","doi-asserted-by":"crossref","first-page":"4163","DOI":"10.1021\/acs.jmedchem.1c00079","volume":"64","author":"Y Wang","year":"2021","unstructured":"Wang Y, Wang X, Xu G, Gou S. Novel CK2-specific Pt(II) compound reverses Cisplatin-induced resistance by inhibiting Cancer cell Stemness and suppressing DNA damage repair in non-small cell lung Cancer treatments. J Med Chem. 2021;64:4163\u201378.","journal-title":"J Med Chem"},{"key":"1455_CR6","doi-asserted-by":"crossref","first-page":"3420","DOI":"10.1096\/fj.201800618RRR","volume":"33","author":"J Zhou","year":"2019","unstructured":"Zhou J, Chen Q. Poor expression of microRNA-135b results in the inhibition of cisplatin resistance and proliferation and induces the apoptosis of gastric cancer cells through MST1-mediated MAPK signaling pathway. FASEB J. 2019;33:3420\u201336.","journal-title":"FASEB J"},{"key":"1455_CR7","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s12943-019-0969-3","volume":"18","author":"X Huang","year":"2019","unstructured":"Huang X, Li Z, Zhang Q, Wang W, Li B, Wang L, et al. Circular RNA AKT3 upregulates PIK3R1 to enhance cisplatin resistance in gastric cancer via miR-198 suppression. Mol Cancer. 2019;18:71.","journal-title":"Mol Cancer"},{"key":"1455_CR8","doi-asserted-by":"crossref","first-page":"2082","DOI":"10.1002\/med.21574","volume":"39","author":"Q Wu","year":"2019","unstructured":"Wu Q, Wu W, Fu B, Shi L, Wang X, Kuca K. JNK signaling in cancer cell survival. Med Res Rev. 2019;39:2082\u2013104.","journal-title":"Med Res Rev"},{"key":"1455_CR9","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-020-01171-z","volume":"19","author":"X Zhang","year":"2020","unstructured":"Zhang X, Xie K, Zhou H, Wu Y, Li C, Liu Y, et al. Role of non-coding RNAs and RNA modifiers in cancer therapy resistance. Mol Cancer. 2020;19:47.","journal-title":"Mol Cancer"},{"key":"1455_CR10","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41568-020-00306-0","volume":"21","author":"GJ Goodall","year":"2021","unstructured":"Goodall GJ, Wickramasinghe VO. RNA in cancer. Nat Rev Cancer. 2021;21:22\u201336.","journal-title":"Nat Rev Cancer"},{"key":"1455_CR11","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","volume":"22","author":"L Statello","year":"2021","unstructured":"Statello L, Guo CJ, Chen LL, Huarte M. Gene regulation by long non-coding RNAs and its biological functions. Nat Rev Mol Cell Biol. 2021;22:96\u2013118.","journal-title":"Nat Rev Mol Cell Biol"},{"key":"1455_CR12","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/s12943-020-01206-5","volume":"19","author":"Y Liang","year":"2020","unstructured":"Liang Y, Song X, Li Y, Chen B, Zhao W, Wang L, et al. LncRNA BCRT1 promotes breast cancer progression by targeting miR-1303\/PTBP3 axis. Mol Cancer. 2020;19:85.","journal-title":"Mol Cancer"},{"key":"1455_CR13","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s12943-020-01237-y","volume":"19","author":"C Zhou","year":"2020","unstructured":"Zhou C, Yi C, Yi Y, Qin W, Yan Y, Dong X, et al. LncRNA PVT1 promotes gemcitabine resistance of pancreatic cancer via activating Wnt\/\u03b2-catenin and autophagy pathway through modulating the miR-619-5p\/Pygo2 and miR-619-5p\/ATG14 axes. Mol Cancer. 2020;19:118.","journal-title":"Mol Cancer"},{"key":"1455_CR14","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.3389\/fonc.2019.01103","volume":"9","author":"N Huang","year":"2019","unstructured":"Huang N, Guo W, Ren K, Li W, Jiang Y, Sun J, et al. LncRNA AFAP1-AS1 Supresses miR-139-5p and promotes cell proliferation and chemotherapy resistance of non-small cell lung Cancer by competitively Upregulating RRM2. Front Oncol. 2019;9:1103.","journal-title":"Front Oncol"},{"key":"1455_CR15","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s13046-021-01844-7","volume":"40","author":"M Zhang","year":"2021","unstructured":"Zhang M, Wang Y, Jiang L, Song X, Zheng A, Gao H, et al. LncRNA CBR3-AS1 regulates of breast cancer drug sensitivity AS a competing endogenous RNA through the JNK1\/MEK4-mediated MAPK signal pathway. J Exp Clin Cancer Res. 2021;40:41.","journal-title":"J Exp Clin Cancer Res"},{"key":"1455_CR16","doi-asserted-by":"crossref","first-page":"4000","DOI":"10.1200\/JCO.2016.68.7798","volume":"34","author":"A Bagrodia","year":"2016","unstructured":"Bagrodia A, Lee BH, Lee W, Cha EK, Sfakianos JP, Iyer G, et al. Genetic determinants of Cisplatin resistance in patients with advanced germ cell tumors. J Clin Oncol. 2016;34:4000\u20137.","journal-title":"J Clin Oncol"},{"key":"1455_CR17","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(\u2212Delta Delta C(T)) method. Methods. 2001;25:402\u20138.","journal-title":"Methods"},{"key":"1455_CR18","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/hep.29270","volume":"66","author":"D Han","year":"2017","unstructured":"Han D, Li J, Wang H, Su X, Hou J, Gu Y, et al. Circular RNA circMTO1 acts as the sponge of microRNA-9 to suppress hepatocellular carcinoma progression. Hepatology. 2017;66:1151\u201364.","journal-title":"Hepatology"},{"key":"1455_CR19","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.canlet.2004.01.038","volume":"211","author":"H Toshimitsu","year":"2004","unstructured":"Toshimitsu H, Hashimoto K, Tangoku A, Iizuka N, Yamamoto K, Kawauchi S, et al. Molecular signature linked to acquired resistance to cisplatin in esophageal cancer cells. Cancer Lett. 2004;211:69\u201378.","journal-title":"Cancer Lett"},{"key":"1455_CR20","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1002\/jcb.29366","volume":"121","author":"J Wang","year":"2020","unstructured":"Wang J, Liu T, Wang M, Lv W, Wang Y, Jia Y, et al. SRSF1-dependent alternative splicing attenuates BIN1 expression in non-small cell lung cancer. J Cell Biochem. 2020;121:946\u201353.","journal-title":"J Cell Biochem"},{"key":"1455_CR21","doi-asserted-by":"crossref","first-page":"1095","DOI":"10.1002\/ijc.29481","volume":"137","author":"Y Jia","year":"2015","unstructured":"Jia Y, Wang H, Wang Y, Wang T, Wang M, Ma M, et al. Low expression of Bin1, along with high expression of IDO in tumor tissue and draining lymph nodes, are predictors of poor prognosis for esophageal squamous cell cancer patients. Int J Cancer. 2015;137:1095\u2013106.","journal-title":"Int J Cancer"},{"key":"1455_CR22","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1038\/s41419-019-1811-y","volume":"10","author":"Y Jia","year":"2019","unstructured":"Jia Y, Duan Y, Liu T, Wang X, Lv W, Wang M, et al. LncRNA TTN-AS1 promotes migration, invasion, and epithelial mesenchymal transition of lung adenocarcinoma via sponging miR-142-5p to regulate CDK5. Cell Death Dis. 2019;10:573.","journal-title":"Cell Death Dis"},{"key":"1455_CR23","doi-asserted-by":"crossref","first-page":"7252","DOI":"10.1158\/1078-0432.CCR-04-0713","volume":"10","author":"RL Camp","year":"2004","unstructured":"Camp RL, Dolled-Filhart M, Rimm DL. X-tile: a new bio-informatics tool for biomarker assessment and outcome-based cut-point optimization. Clin Cancer Res. 2004;10:7252\u20139.","journal-title":"Clin Cancer Res"},{"key":"1455_CR24","first-page":"575","volume":"70","author":"T Nishihira","year":"1979","unstructured":"Nishihira T, Kasai M, Mori S, Watanabe T, Kuriya Y, Suda M, et al. Characteristics of two cell lines (TE-1 and TE-2) derived from human squamous cell carcinoma of the esophagus. Gan. 1979;70:575\u201384.","journal-title":"Gan"},{"key":"1455_CR25","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1002\/1097-0142(19920115)69:2<277::AID-CNCR2820690202>3.0.CO;2-C","volume":"69","author":"Y Shimada","year":"1992","unstructured":"Shimada Y, Imamura M, Wagata T, Yamaguchi N, Tobe T. Characterization of 21 newly established esophageal cancer cell lines. Cancer. 1992;69:277\u201384.","journal-title":"Cancer"},{"key":"1455_CR26","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1186\/s13046-018-0724-4","volume":"37","author":"ZW Chang","year":"2018","unstructured":"Chang ZW, Jia YX, Zhang WJ, Song LJ, Gao M, Li MJ, et al. LncRNA-TUSC7\/miR-224 affected chemotherapy resistance of esophageal squamous cell carcinoma by competitively regulating DESC1. J Exp Clin Cancer Res. 2018;37:56.","journal-title":"J Exp Clin Cancer Res"},{"key":"1455_CR27","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.canlet.2014.07.044","volume":"354","author":"H Zhu","year":"2014","unstructured":"Zhu H, Chen X, Chen B, Chen B, Fan J, Song W, et al. Activating transcription factor 4 mediates a multidrug resistance phenotype of esophageal squamous cell carcinoma cells through transactivation of STAT3 expression. Cancer Lett. 2014;354:142\u201352.","journal-title":"Cancer Lett"},{"key":"1455_CR28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1093\/carcin\/bgz065","volume":"41","author":"K Zhu","year":"2020","unstructured":"Zhu K, Peng Y, Hu J, Zhan H, Yang L, Gao Q, et al. Metadherin-PRMT5 complex enhances the metastasis of hepatocellular carcinoma through the WNT-\u03b2-catenin signaling pathway. Carcinogenesis. 2020;41:130\u20138.","journal-title":"Carcinogenesis"},{"key":"1455_CR29","doi-asserted-by":"crossref","unstructured":"Nguyen YT, Moon JY, Ediriweera MK, Cho SK. Phenethyl Isothiocyanate suppresses Stemness in the chemo- and radio-resistant triple-negative breast Cancer cell line MDA-MB-231\/IR via Downregulation of Metadherin. Cancers (Basel). 2020;12.","DOI":"10.3390\/cancers12020268"},{"key":"1455_CR30","doi-asserted-by":"crossref","first-page":"349","DOI":"10.3389\/fonc.2019.00349","volume":"9","author":"G Dhiman","year":"2019","unstructured":"Dhiman G, Srivastava N, Goyal M, Rakha E, Lothion-Roy J, Mongan NP, et al. Metadherin: a therapeutic target in multiple cancers. Front Oncol. 2019;9:349.","journal-title":"Front Oncol"},{"key":"1455_CR31","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1186\/s12943-019-1095-y","volume":"18","author":"X Hu","year":"2019","unstructured":"Hu X, Wu D, He X, Zhao H, He Z, Lin J, et al. circGSK3\u03b2 promotes metastasis in esophageal squamous cell carcinoma by augmenting \u03b2-catenin signaling. Mol Cancer. 2019;18:160.","journal-title":"Mol Cancer"},{"key":"1455_CR32","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s12943-017-0669-9","volume":"16","author":"A Liu","year":"2017","unstructured":"Liu A, Zhu J, Wu G, Cao L, Tan Z, Zhang S, et al. Antagonizing miR-455-3p inhibits chemoresistance and aggressiveness in esophageal squamous cell carcinoma. Mol Cancer. 2017;16:106.","journal-title":"Mol Cancer"},{"key":"1455_CR33","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/j.jcmgh.2018.09.003","volume":"7","author":"T Kijima","year":"2019","unstructured":"Kijima T, Nakagawa H, Shimonosono M, Chandramouleeswaran PM, Hara T, Sahu V, et al. Three-dimensional Organoids reveal therapy resistance of esophageal and Oropharyngeal squamous cell carcinoma cells. Cell Mol Gastroenterol Hepatol. 2019;7:73\u201391.","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"1455_CR34","doi-asserted-by":"crossref","first-page":"12051","DOI":"10.1002\/jcp.27869","volume":"234","author":"X Yang","year":"2019","unstructured":"Yang X, Cai JB, Peng R, Wei CY, Lu JC, Gao C, et al. The long noncoding RNA NORAD enhances the TGF-\u03b2 pathway to promote hepatocellular carcinoma progression by targeting miR-202-5p. J Cell Physiol. 2019;234:12051\u201360.","journal-title":"J Cell Physiol"},{"key":"1455_CR35","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1038\/s41586-018-0453-z","volume":"561","author":"M Munschauer","year":"2018","unstructured":"Munschauer M, Nguyen CT, Sirokman K, Hartigan CR, Hogstrom L, Engreitz JM, et al. The NORAD lncRNA assembles a topoisomerase complex critical for genome stability. Nature. 2018;561:132\u20136.","journal-title":"Nature"},{"key":"1455_CR36","doi-asserted-by":"crossref","first-page":"1744","DOI":"10.1002\/cam4.2046","volume":"8","author":"Y Chen","year":"2019","unstructured":"Chen Y, Cao K, Li J, Wang A, Sun L, Tang J, et al. Overexpression of long non-coding RNA NORAD promotes invasion and migration in malignant melanoma via regulating the MIR-205-EGLN2 pathway. Cancer Med. 2019;8:1744\u201354.","journal-title":"Cancer Med"},{"key":"1455_CR37","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1186\/s12943-017-0738-0","volume":"16","author":"H Li","year":"2017","unstructured":"Li H, Wang X, Wen C, Huo Z, Wang W, Zhan Q, et al. Long noncoding RNA NORAD, a novel competing endogenous RNA, enhances the hypoxia-induced epithelial-mesenchymal transition to promote metastasis in pancreatic cancer. Mol Cancer. 2017;16:169.","journal-title":"Mol Cancer"},{"key":"1455_CR38","doi-asserted-by":"crossref","first-page":"2211","DOI":"10.1111\/cas.13626","volume":"109","author":"N Kawasaki","year":"2018","unstructured":"Kawasaki N, Miwa T, Hokari S, Sakurai T, Ohmori K, Miyauchi K, et al. Long noncoding RNA NORAD regulates transforming growth factor-\u03b2 signaling and epithelial-to-mesenchymal transition-like phenotype. Cancer Sci. 2018;109:2211\u201320.","journal-title":"Cancer Sci"},{"key":"1455_CR39","doi-asserted-by":"crossref","first-page":"670917","DOI":"10.3389\/fonc.2021.670917","volume":"11","author":"S Ghafouri-Fard","year":"2021","unstructured":"Ghafouri-Fard S, Agabalazadeh A, Abak A, Shoorei H, Hassanzadeh Taheri MM, Taheri M, et al. Role of long non-coding RNAs in conferring resistance in tumors of the nervous system. Front Oncol. 2021;11:670917.","journal-title":"Front Oncol"},{"key":"1455_CR40","doi-asserted-by":"crossref","first-page":"110268","DOI":"10.1016\/j.biopha.2020.110268","volume":"129","author":"B Wang","year":"2020","unstructured":"Wang B, Xu L, Zhang J, Cheng X, Xu Q, Wang J, et al. LncRNA NORAD accelerates the progression and doxorubicin resistance of neuroblastoma through up-regulating HDAC8 via sponging miR-144-3p. Biomed Pharmacother. 2020;129:110268.","journal-title":"Biomed Pharmacother"},{"key":"1455_CR41","doi-asserted-by":"crossref","unstructured":"Huang Q, Xing S, Peng A, Yu Z. NORAD accelerates chemo-resistance of non-small-cell lung cancer via targeting at miR-129-1-3p\/SOX4 axis. Biosci Rep.\u00a02020;40:BSR20193489.","DOI":"10.1042\/BSR20193489"},{"key":"1455_CR42","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/s41419-020-03368-y","volume":"12","author":"J Wang","year":"2021","unstructured":"Wang J, Sun Y, Zhang X, Cai H, Zhang C, Qu H, et al. Oxidative stress activates NORAD expression by H3K27ac and promotes oxaliplatin resistance in gastric cancer by enhancing autophagy flux via targeting the miR-433-3p. Cell Death Dis. 2021;12:90.","journal-title":"Cell Death Dis"},{"key":"1455_CR43","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1159\/000464465","volume":"40","author":"X Wu","year":"2017","unstructured":"Wu X, Lim ZF, Li Z, Gu L, Ma W, Zhou Q, et al. NORAD expression is associated with adverse prognosis in esophageal squamous cell carcinoma. Oncol Res Treat. 2017;40:370\u20134.","journal-title":"Oncol Res Treat"},{"key":"1455_CR44","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1016\/j.tibs.2016.07.003","volume":"41","author":"LL Chen","year":"2016","unstructured":"Chen LL. Linking long noncoding RNA localization and function. Trends Biochem Sci. 2016;41:761\u201372.","journal-title":"Trends Biochem Sci"},{"key":"1455_CR45","doi-asserted-by":"crossref","first-page":"12209","DOI":"10.1038\/ncomms12209","volume":"7","author":"A Tichon","year":"2016","unstructured":"Tichon A, Gil N, Lubelsky Y, Havkin Solomon T, Lemze D, Itzkovitz S, et al. A conserved abundant cytoplasmic long noncoding RNA modulates repression by Pumilio proteins in human cells. Nat Commun. 2016;7:12209.","journal-title":"Nat Commun"},{"key":"1455_CR46","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1038\/s41419-020-2674-y","volume":"11","author":"T Han","year":"2020","unstructured":"Han T, Wu Y, Hu X, Chen Y, Jia W, He Q, et al. NORAD orchestrates endometrial cancer progression by sequestering FUBP1 nuclear localization to promote cell apoptosis. Cell Death Dis. 2020;11:473.","journal-title":"Cell Death Dis"},{"key":"1455_CR47","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.omtn.2019.03.011","volume":"16","author":"H Liu","year":"2019","unstructured":"Liu H, Wang S, Zhou S, Meng Q, Ma X, Song X, et al. Drug resistance-related competing interactions of lncRNA and mRNA across 19 Cancer types. Mol Ther Nucleic Acids. 2019;16:442\u201351.","journal-title":"Mol Ther Nucleic Acids"},{"key":"1455_CR48","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/s41419-020-2735-2","volume":"11","author":"X Fang","year":"2020","unstructured":"Fang X, Zhong G, Wang Y, Lin Z, Lin R, Yao T. Low GAS5 expression may predict poor survival and cisplatin resistance in cervical cancer. Cell Death Dis. 2020;11:531.","journal-title":"Cell Death Dis"},{"key":"1455_CR49","doi-asserted-by":"crossref","first-page":"585251","DOI":"10.3389\/fcell.2020.585251","volume":"8","author":"F Yan","year":"2020","unstructured":"Yan F, Zhao W, Xu X, Li C, Li X, Liu S, et al. LncRNA DHRS4-AS1 inhibits the Stemness of NSCLC cells by sponging miR-224-3p and Upregulating TP53 and TET1. Front Cell Dev Biol. 2020;8:585251.","journal-title":"Front Cell Dev Biol"},{"key":"1455_CR50","doi-asserted-by":"crossref","first-page":"e12515","DOI":"10.1111\/cpr.12515","volume":"51","author":"R Xu","year":"2018","unstructured":"Xu R, Feng F, Yu X, Liu Z, Lao L. LncRNA SNHG4 promotes tumour growth by sponging miR-224-3p and predicts poor survival and recurrence in human osteosarcoma. Cell Prolif. 2018;51:e12515.","journal-title":"Cell Prolif"},{"key":"1455_CR51","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.gene.2005.04.006","volume":"353","author":"DC Kang","year":"2005","unstructured":"Kang DC, Su ZZ, Sarkar D, Emdad L, Volsky DJ, Fisher PB. Cloning and characterization of HIV-1-inducible astrocyte elevated gene-1, AEG-1. Gene. 2005;353:8\u201315.","journal-title":"Gene"},{"key":"1455_CR52","doi-asserted-by":"crossref","unstructured":"Manna D, Sarkar D. Multifunctional role of astrocyte elevated gene-1 (AEG-1) in cancer: focus on drug Resistance. Cancers (Basel); 2021;13:1792.","DOI":"10.3390\/cancers13081792"},{"key":"1455_CR53","doi-asserted-by":"crossref","unstructured":"Khan M, Sarkar D. The scope of astrocyte elevated Gene-1\/Metadherin (AEG-1\/MTDH) in Cancer Clinicopathology: A Review. Genes (Basel).\u00a02021;12:308.","DOI":"10.3390\/genes12020308"},{"key":"1455_CR54","doi-asserted-by":"crossref","first-page":"3357","DOI":"10.1038\/onc.2011.500","volume":"31","author":"XX He","year":"2012","unstructured":"He XX, Chang Y, Meng FY, Wang MY, Xie QH, Tang F, et al. MicroRNA-375 targets AEG-1 in hepatocellular carcinoma and suppresses liver cancer cell growth in vitro and in vivo. Oncogene. 2012;31:3357\u201369.","journal-title":"Oncogene"}],"container-title":["Molecular Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12943-021-01455-y\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12943-021-01455-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,12,10]],"date-time":"2021-12-10T00:05:06Z","timestamp":1639094706000},"score":1,"resource":{"primary":{"URL":"https:\/\/molecular-cancer.biomedcentral.com\/articles\/10.1186\/s12943-021-01455-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":54,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1455"],"URL":"https:\/\/doi.org\/10.1186\/s12943-021-01455-y","relation":{},"ISSN":["1476-4598"],"issn-type":[{"value":"1476-4598","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"19 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The present study was approved by the Fourth Hospital of Hebei Medical University. All patients signed informed consents before surgery. Animal studies were approved by the Institutional Animal Care and Use Committee of Fourth Hospital of Hebei Medical University.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"162"}}